Petros Pharmaceuticals annual net debt
2020
2021
2022
2023
2024
Petros Pharmaceuticals Net Debt Growth & History (PTPI)
Petros Pharmaceuticals's net debt was −$1.6M for fiscal 2024.
View full Petros Pharmaceuticals company overviewPetros Pharmaceuticals annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | −$1.6M | $11.5M | — |
| 2023 | 2023-12-31 | −$13.1M | −$4.1M | — |
| 2022 | 2022-12-31 | −$9.0M | $14.3M | — |
| 2021 | 2021-12-31 | −$23.3M | −$14.0M | — |
| 2020 | 2020-12-31 | −$9.3M | — | — |
Petros Pharmaceuticals quarterly net debt
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q4.24
Q1.25
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q1 2025 | 2025-03-31 | −$1.7M | — | — |
| Q4 2024 | 2024-12-31 | −$1.6M | $11.5M | — |
| Q4 2023 | 2023-12-31 | −$13.1M | −$4.1M | — |
| Q3 2023 | 2023-09-30 | −$17.7M | −$6.9M | — |
| Q2 2023 | 2023-06-30 | −$7.1M | $5.8M | — |
| Q1 2023 | 2023-03-31 | −$7.9M | $9.2M | — |
| Q4 2022 | 2022-12-31 | −$9.0M | $14.3M | — |
| Q3 2022 | 2022-09-30 | −$10.8M | −$4.9M | — |
| Q2 2022 | 2022-06-30 | −$12.8M | −$5.8M | — |
| Q1 2022 | 2022-03-31 | −$17.2M | −$8.3M | — |
| Q4 2021 | 2021-12-31 | −$23.3M | −$14.0M | — |
| Q3 2021 | 2021-09-30 | −$5.8M | — | — |
| Q2 2021 | 2021-06-30 | −$7.0M | — | — |
| Q1 2021 | 2021-03-31 | −$8.9M | — | — |
| Q4 2020 | 2020-12-31 | −$9.3M | — | — |
Petros Pharmaceuticals net debt trends
Between the periods ended 2020-12-31 and 2024-12-31, Petros Pharmaceuticals's net debt increased from −$9.3M to −$1.6M, a change of $7.7M. The latest reported quarter, Q1 2025, shows −$1.7M.
About the metric
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
Calculation and source
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Petros Pharmaceuticals source filings ↗